Abstract: The present invention belongs to the field of pharmaceutical manufacturing technology. The present invention provides a pharmaceutical composition of a conjugate and a preparation method thereof. The pharmaceutical composition is preferably administered by injection. The docetaxel conjugate has a structural formula as shown in the following formula: (I).

Abstract: The present invention relates to a process for preparing a metal-chelate retarder by a sol-gel method. The method comprises the following steps: weighing calcium nitrate tetrahydrate, aluminum nitrate nonahydrate and ferric nitrate nonahydrate according to a certain mass ratio and adding them into deionized water; placing the mixed solution on a magnetic stirrer and stirring the mixed solution evenly; adding citric acid monohydrate or gluconic acid, ethylene glycol or glycerol, and placing the mixed solution into a water bath to react to obtain the metal-chelate retarder. The process of the present invention has a reliable principle, overcomes the defects of long production period, complex preparation and the like of the existing retarders, has the advantages of simple process operation, cheap and easily available raw materials, and short production period.

Abstract: The present disclosure discloses a cleaning robot, including a water tank, a dust box, and a main body. The water tank and the dust box are assembled together to form a water tank dust box assembly. The main body includes an accommodating space adapted to accommodate the water tank dust box assembly. The water tank dust box assembly includes a mistake-proofing device. The mistake-proofing device, when the water tank and the dust box are not assembled to form the water tank dust box assembly, is in an ejected state so that the water tank or the dust box cannot be installed into the accommodating space.

Abstract: The present invention relates to a process for preparing a metal-chelate retarder by a sol-gel method. The method comprises the following steps: weighing calcium nitrate tetrahydrate, aluminum nitrate nonahydrate and ferric nitrate nonahydrate according to a certain mass ratio and adding them into deionized water; placing the mixed solution on a magnetic stirrer and stirring the mixed solution evenly; adding citric acid monohydrate or gluconic acid, ethylene glycol or glycerol, and placing the mixed solution into a water bath to react to obtain the metal-chelate retarder. The process of the present invention has a reliable principle, overcomes the defects of long production period, complex preparation and the like of the existing retarders, has the advantages of simple process operation, cheap and easily available raw materials, and short production period.

Abstract: The present disclosure discloses a cleaning robot, including a water tank, a dust box, and a main body. The water tank and the dust box are assembled together to form a water tank dust box assembly. The main body includes an accommodating space adapted to accommodate the water tank dust box assembly. The water tank dust box assembly includes a mistake-proofing device. The mistake-proofing device, when the water tank and the dust box are not assembled to form the water tank dust box assembly, is in an ejected state so that the water tank or the dust box cannot be installed into the accommodating space.

Abstract: The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention provides (4-{4-[5-(Benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid which is useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention provides organic compounds of the following structure; A-L1-B—C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention provides organic compounds of the following structure; A-L1-B—C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

Abstract: The present invention relates to an improved process for preparing certain substituted caprolactam compounds which comprises acylating an aminocaprolactam compound with a lactone compound in the presence of a weak base and a polar, organic solvent, and hydrolyzing the resultant diamide compound in a mixture of solvents to obtain the desired caprolactam compound.

Abstract: The present invention relates to an improved process for preparing certain substituted caprolactam compounds which comprises acylating an aminocaprolactam compound with a lactone compound in the presence of a weak base and a polar, organic solvent, and hydrolyzing the resultant diamide compound in a mixture of solvents to obtain the desired caprolactam compound.